



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Olejnik et al. )

Group Art Unit: 1615

Serial No.: 10/691,912 )

Conf. No.: 6640 )

Filed: October 22, 2003 )

For: Compositions Containing  
Alpha-2-Adrenergic Agonist  
Components )

Examiner: Not yet assigned )

I hereby certify that this correspondence is being deposited with the  
United States Postal Service with sufficient postage as First Class  
Mail in an envelope addressed to: Mail Stop Supplemental  
Information Disclosure Statement-Non Fee, Commissioner for  
Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date of Deposit: 2/27/2004

Person making Deposit: Bonnie Ferguson

Signature: Bonnie Ferguson

Date of Signature:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

The references listed on the attached Supplemental PTO-1449 form are being brought to the attention of the Examiner for consideration in connection with the examination of the above-captioned application.

This Supplemental IDS is being submitted prior to the mailing of a first office action in this case; therefore, no fee is believed due in connection with this communication. If, however, a first office action is mailed prior to the mailing date of this Supplemental IDS, please consider this communication a Petition under 37 C.F.R. § 1.97(c) and charge Deposit Account No. 010885 the appropriate amount.


17361CON2(AP)  
Serial No. 10/691,912

PATENT  
Page 2

Applicants respectfully request that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO-1449 with the Examiner's initials or other appropriate marks.

Date: 2/22/04

Respectfully submitted,



Carlos A. Fisher  
Reg. No. 36,510  
ALLERGAN, INC.  
T2-7H  
2525 Dupont Drive  
Irvine, CA 92612  
Tel: 714-246-4920  
Fax: 714-246-4249



**LIST OF REFERENCES CITED BY APPLICANT**

<b>ATTY. DOCKET:</b> 17361CON2(AP)	<b>SERIAL NO.:</b> 10/691,912
<b>APPLICANT:</b> Olejnuk et al	<b>TITLE:</b> COMPOSITIONS CONTAINING ALPHA 2-ADRENERGIC AGONIST COMPONENTS
<b>FILING DATE:</b> 22 October 2003	<b>GROUP:</b> 1615

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
BA	3,300,511	1/24/1967	Stahle et al			

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
BB	0426390	8 May 1991	EP			
BC	0550921	14 July 1993	EP			
BE	0049990	31 Aug. 2000	WO			

**OTHER REFERENCES**

(Including Author, Title, Date, Pertinent Pages, etc.)

BD	Abstract-XP-002190601-JP 05271053, 19 October 1993
BE	K. Parfitt (ED): "Martindale, the complete drug reference", 1999, Thirty-second edition, page 834, left-hand column, line 24, line 52
BF	A. Osol (ED): "Remington's Pharmaceutical Sciences", 1980, 16 <sup>th</sup> Edition, Chapter 86: Ophthalmic preparations, page 1498-1517

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.